Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 91 publications
Incidence and Associated Risk Factors in the Development of Carfilzomib-Induced Cardiovascular Toxicity.
Journal: Current oncology (Toronto, Ont.)
Published: June 22, 2026
Impact Of Conditioning Intensity on Outcomes After Unrelated Donor Hematopoietic Cell Transplantation Using Post-Transplant Cyclophosphamide-Based GVHD Prophylaxis.
Journal: Transplantation and cellular therapy
Published: June 21, 2026
From episodic assessment to comprehensive assessment: integrating real-world monitoring in relapsed/refractory multiple myeloma.
Journal: Expert review of hematology
Published: May 27, 2026
Outcomes With Immunotherapy in Hormone Receptor-Positive Breast Cancer: A Systematic Review and Meta-Analysis.
Journal: American journal of clinical oncology
Published: May 15, 2026
Outcomes After Matched Sibling Donor Versus Haploidentical Hematopoietic Stem Cell Transplantation With Post-Transplant Cyclophosphamide-Based GVHD Prophylaxis.
Journal: Transplantation and cellular therapy
Published: May 13, 2026
The ClinicalTrials.gov Landscape of Multiple Myeloma Clinical Trials: A 20-Year Analysis of Geographic Distribution and Growth Patterns: USMIRC Analysis.
Journal: Current oncology (Toronto, Ont.)
Published: May 05, 2026
Impact of CD34+ Graft Cell Dose on Outcomes after Haploidentical Bone Marrow Transplantation with Post-Transplant Cyclophosphamide-Based GVHD Prophylaxis.
Journal: Transplantation and cellular therapy
Published: April 23, 2026
Outcomes of Hematopoietic Cell Transplantation With Post-Transplant Cyclophosphamide-Based GVHD Prophylaxis in Acute Myeloid Leukemia and Myelodysplastic Syndromes Patients Over 70 Years of Age: A Comparative Analysis by Age Group.
Journal: Clinical lymphoma, myeloma & leukemia
Published: March 25, 2026
Long-Term Gynecologic and Reproductive Health in Female Survivors of Allogeneic Hematopoietic Stem Cell Transplantation: A Systematic Review and Meta-analysis of Prevalence.
Journal: Transplantation and cellular therapy
Published: March 14, 2026
Outcomes of Double-Hit and Single High-Risk Cytogenetic Newly Diagnosed Myeloma in Transplant-Eligible Patients.
Journal: Current oncology (Toronto, Ont.)
Published: March 09, 2026
Maintenance Strategies in High-Risk Myeloma: A Multicenter Comparison of Bortezomib-Lenalidomide Versus Lenalidomide Alone: A USMIRC Multicenter Analysis.
Journal: Current oncology (Toronto, Ont.)
Published: January 30, 2026
A Real-World Analysis of the Safety and Efficacy of Teclistamab for Patients with Relapsed/Refractory Multiple Myeloma and Baseline Renal Impairment-USMIRC Group.
Journal: Cancers
Published: December 12, 2025
Last Updated: 09/26/2026